Media Release: Hydrix Designs & Engineers Technologies Which Enhance People’s Health, Safety & Wellbeing
- The Guardian System is the world’s first FDA approved implantable heart attack alert system using patented AI & Machine learning algorithms.
Australian product design & engineering company Hydrix Limited (ASX: HYD) (“Hydrix” or “Company”) has been helping technology companies to commercialise innovative products in the medical devices, consumer, industrial, mining and defence space for around 20 years.
Based out of their state-of-the-art facility in Mulgrave, Victoria, Hydrix partners with companies to help design, develop and commercialise their transformative technologies which enhance people’s health, safety and wellbeing. Hydrix provides clients with world class product engineering know-how to de-risk product development, create market-leading solutions and accelerate go to market strategies. The Company is leveraging this expertise into IP and product ownership to generate long-term recurring product revenues.
Hydrix has created ground-breaking solutions for clients operating in three large and growing sectors – Medical Technology, Consumer & Industrials, and Defence & Rail. The Company is leveraging 1,000s of years of technology commercialisation experience and know-how to capture more of the value it creates through its Buy, Build & Invest strategy. One key example of this strategy is Hydrix’s partnership with Angel Medical Systems, Inc (AngelMed). Hydrixentered into a services agreement to assist in the development of product upgrades of the Guardian® System (Guardian) device, entered into an exclusive distribution agreement for parts of Asia Pacific, and made an investment in the company. The Guardian System is the world’s first FDA approved implantable heart attack alert system using patented AI & Machine learning algorithms.
Cardiovascular diseases affect ~14% of the population, responsible for an estimated 31% of all deaths worldwide, with 85% of these due to heart attack and stroke. Alarmingly, 45% of heart attacks are silent, where the patient has no recognisable symptoms. The Guardian device is surgically implanted and monitors the heart 24/7. It detects heart-beat changes indicative of a potential heart attack, angina attack and arrhythmias, and can raise the alarm before a potentially fatal heart attack, giving the patient enough time to get the required care.
In commenting on the partnership between Hydrix and AngelMed, Gavin Coote, Hydrix Executive Chairman, said:
“The AngelMed Guardian System is the most significant and only implantable device for early warning of heart attacks and has the potential to transform Hydrix.
“The Guardian System has been proven to alert patients to seek immediate medical attention due to an impending Acute Coronary Syndrome (ACS) event caused by a partial or complete blockage of blood flow and oxygen to the heart.”
Hydrix’s work in the medtech innovation sector has also seen them collaborate and partner with companies including the development of an orthopaedic tool to improve hip replacement surgery patient outcomes; non-invasive monitoring of brain oxygen levels in patients who have suffered a brain trauma injury; and bio-separation technology for use in human in vitro fertilisation (IVF).
Hydrix Limited (ASX:HYD) is an Australian product design and engineering company, specialising in complex, regulated and safety-critical projects. They partner with clients to help design, develop and commercialise transformative technologies in sectors including medical, mining, industrial and defence.
For more information please visit:
For further information please contact:
Rod North, Managing Director,
Bourse Communications Pty Ltd
T: (03) 9510 8309, M: 0408 670 706,
E: [email protected]